GNOM News and Press, Global X Genomics & Biotechnology ETF From 04/16/21

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of thi...

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those ...

In our opinion, telehealth will remain the leading segment of the internet healthcare market as the market shifts away from in-person medical visits. According to Apple CEO Tim Cook, “I believe, if you zoom out into the future, and you look back, and you ask the question, ...

The ARK Genomic Revolution Multi-Sector ETF has delivered the best return of all ARK funds over the last year, rising 173%. However, it's also one of the riskier ARK funds, going by both quantifiable measures and "soft" factors. In this article, I develop a neutral thesis on ARKG,...

Risk assets continued their historic run last week with EM equities and commodities leading the way. Bonds sold off as the 10-year Treasury note yield broke above 1.20% for the first time since the lows last spring. The 10-year TIPS yield closed the week at 1.02%, near the all-tim...

After a dramatic year of volatility, the U.S. stock market ended 2020 at record highs. Can this momentum continue this year? ESG investments clearly outperformed in 2020. 2021 should be a year of much better cash flow for companies. For further details see: A Stock Picke...

2020 was a busy year for global healthcare with unprecedented efforts to develop vaccines, treatments, and diagnostics for COVID-19. Deal flow in the sector continued to gain momentum in 2020, with M&A transactions and product licensing deals totalling five-year highs as large-cap...

Gainers: S&P Biotech Bear 3X Direxion (LABD) +22.6%.South Korea Bull 3X Direxion (KORU) +20.0%.Utilities Bull 3X Direxion (UTSL) +9.6%.CSI 300 China A 2X Direxion (CHAU) +9.2%.Semiconductor Bull 3X Direxion (SOXL) +7.9%.Losers: S&P Biotech Bull 3X Direxion (LA...

The year 2021 is going to be one of radical uncertainty just because there is so much that is unknown about the pandemic, the economy, government policy, etc. The year 2020 was dominated by three things: the pandemic, the Fed's easy monetary policy, and bifurcation of the society, wit...

Recent positive developments in COVID-19 vaccines have spurred a wave of market exuberance, lifting share prices of biotech companies at the forefront of the vaccine race. COVID-19 and the urgency to find a cure have opened up opportunities, making the biotech sector a prospective spa...